The Memo: Batea Oncology Taking a New Mechanical Approach to Glioblastoma

Under the direction of Sonia Martínez Arca, PhD, Batea Oncology is developing what it describes as the first mechanomedicine platform for cancer, beginning with glioblastoma, one of oncology’s deadliest and most treatment-resistant diseases. Rather than relying on traditional pharmacological approaches, the company’s implantable medical device leverages the mechanical behavior of cancer cells to capture them after surgery and improve their response to radiotherapy. As Batea Oncology prepares to begin its first-in-human clinical trial, the company is working to establish an entirely new therapeutic paradigm for solid tumors with high recurrence rates.

Origin Story

Batea Oncology was founded with a straightforward goal: translate promising laboratory discoveries into therapies capable of improving outcomes for patients facing some of oncology’s greatest unmet needs.

“Our motivation to create Batea Oncology was to translate the very promising results obtained in the lab to the patients in a real translational manner,” Martínez Arca said. “Our co-founders are linked to the Health Research Institute and the University Clinical Hospital in Santiago de Compostela, and therefore we are strongly aware of the unmet medical needs, in particular in oncology.”

Based in Santiago de Compostela, Spain, the company is initially targeting the European market while planning to expand into the United States. Its long-term ambition extends beyond a single product.

“Our vision is to become the pioneering reference company for mechanomedicine applied to low survival solid tumors,” Martínez Arca said.

The company’s first focus is glioblastoma, where decades of research have produced only modest improvements despite the disease’s devastating prognosis.

The Current Landscape

Glioblastoma remains the most common and aggressive primary brain cancer, with a median life expectancy of only 15 months. More than 240,000 new cases are diagnosed worldwide each year, and incidence continues to rise. Yet the standard treatment has remained largely unchanged since the introduction of the Stupp protocol in 2005, which combines maximal surgical resection with radiotherapy and chemotherapy.

While surgery removes the primary tumor, it cannot eliminate every cancer cell. Residual glioblastoma cells remain along the surgical margins, infiltrate healthy brain tissue, and ultimately drive recurrence. Most patients experience relapse within seven to eight months of diagnosis.

According to Martínez Arca, several biological barriers continue to limit progress. The blood-brain barrier prevents many therapies from reaching the tumor site, while glioblastoma’s highly immunosuppressive microenvironment reduces the effectiveness of both conventional drugs and newer immunotherapies. As a result, many targeted therapies that have transformed treatment in other cancers have failed to deliver meaningful survival benefits in glioblastoma.

Medical devices have emerged as another avenue of innovation, but existing technologies have also faced challenges.

“These shortcomings leave a clear unmet need for a new class of treatment: one that is focal, clinically practical, compatible with standard neurosurgical workflows, and capable of controlling the residual tumor cells that drive recurrence while preserving patients’ quality of life,” Martínez Arca said. “This is what we have developed, starting with a completely new perspective: a mechanobiology-based implantable medical device, named GlioHook.”

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-memo-batea-oncology-taking-a-new-mechanical-approach-to-glioblastoma